Mohammed Albanji

Mohammed Albanji is a Consultant in Pediatric Neurology, Adult and Pediatric Movement Disorders, Botulinum Toxin Treatment, and Neuromodulation.

Qualifications:

• Bachelor of Medicine and Surgery (MBBS), King Abdulaziz University.
• Movement Disorders Fellowship, Western University, Canada.
• Advanced Pediatric Movement Disorders Training, The Hospital for Sick Children (SickKids), University of Toronto, Canada.
• Saudi Board in Pediatric Neurology.
• Postgraduate Diploma in Child Mental Health.
• ADOS-2 and ADI-R Training for Autism Diagnostic Assessment.
• MBA in Health Services Administration, USA.
• Master of Clinical Science in Epidemiology and Research Management, Canada.
• Member of the Saudi Pediatric Neurology Society (SPNS).
• Member of the American Academy of Neurology (AAN).
• Member of the American Academy of Pediatrics (AAP).
• Member of the International Parkinson and Movement Disorder Society (MDS).
• Member of the Canadian College of Health Leaders (CCHL).
• Member of the American College of Healthcare Executives (ACHE).

Cases to be seen:

• Pediatric neurological conditions, including epilepsy and seizures, developmental delay and regression, autism and neurodevelopmental disorders, ADHD, cerebral palsy and spasticity, headache and migraine, and genetic and metabolic neurological disorders.
• Adult and pediatric movement disorders, including Parkinson’s disease and parkinsonism, essential tremor and other tremors, dystonia including cervical dystonia, chorea, myoclonus, ataxia, tics and Tourette syndrome, tardive and drug-induced movement disorders, abnormal gait, and involuntary movements.
• Botulinum toxin treatment for neurological indications, including focal dystonia, spasticity, blepharospasm, hemifacial spasm, and sialorrhea.
• Deep Brain Stimulation (DBS) patient selection, evaluation, programming, and long-term follow-up.
• Intrathecal baclofen pump assessment and management for severe spasticity and dystonia.
• Foslevodopa/foscarbidopa pump therapy for advanced Parkinson’s disease.
• Spinal cord stimulation clinical assessment and follow-up.